University of Minnesota. Driven to Discover.
Flu hospitalizations are also on the rise, with the highest levels in seniors, a pattern often seen in H3N2-dominant seasons.
Milder infections aren't as hard to treat as multi-drug resistant ones and might be easier targets for new therapies.
In response, the FDA said it has already made headway in fixing the problems and will take further steps in 2018.
The CDC said the H3N2-dominant trend will make neuraminidase inhibitor antivirals especially useful this flu season.
The outbreaks involved different strains, including H5N6, H5N1, and H5N8.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.